AnalystsInsight

Joseph Thome (TD Cowen): Analyst Track Record and Price‑Target Accuracy

How often Joseph Thome’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 769 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+1 new rating (XENE)

Key takeaways

  • Joseph Thome ranks #604 of 1,000 analysts in Exent’s scoring (4.8★).
  • 58.6% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 90 days; 63.3% of calls were up 12 months later.
  • Most‑covered stocks: UTHR, ANAB, PTCT, AXSM.
  • Free on Exent: Joseph Thome’s full record, with ratings 3 days after publication.

Joseph Thome’s track record at a glance

Joseph Thome of TD Cowen ranks #604 of the 1,000 analysts Exent scores, with a 4.8★ rating and a focus on healthcare. Over a 7‑year lookback, 58.6% of Joseph’s price targets were reached, 6.2 points above the 52.4% average across all analysts.

MetricJoseph ThomeAll analysts
Price‑target hit rate58.6%52.4%
Median days to hit target90 days91 days
Calls up after 12 months63.3%64.0%
Median 12‑month return of calls+17.3%+13.4%
Hit rate, last 2 years63.2%—
Average worst drop after a call−25.2%—
Ratings in the sample769—
Stocks covered30—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetJoseph Thome
Under 30 days25.7%
30–90 days25.1%
90–180 days19.9%
Over 180 days29.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Joseph Thome covers most

StockRatings in the sample
UTHR27
ANAB26
PTCT25
AXSM25
VRDN25
MIRM23
ALKS22
QURE20

In the past year Joseph’s ratings were 94% Buy, 6% Hold and 0% Sell.

Joseph Thome’s latest ratings

DateStockActionRatingPrice target
Sep 18, 2026XENEReiterated: BuyBuy$0.00
Sep 4, 2026NTLAReiterated: BuyBuy$0.00
Sep 2, 2026QUREReiterated: BuyBuy$0.00
Sep 2, 2026UTHRReiterated: BuyBuy$675.00
Aug 31, 2026JAZZReiterated: BuyBuy$300.00
Aug 30, 2026PTCTReiterated: BuyBuy$90.00
Aug 30, 2026ARWRReiterated: BuyBuy$0.00
Aug 26, 2026JAZZReiterated: BuyBuy$300.00
Aug 25, 2026ANABRated: BuyBuy$0.00
Aug 24, 2026UTHRReiterated: BuyBuy$675.00
Aug 18, 2026AMLXReiterated: BuyBuy$0.00
Aug 16, 2026DRUGReiterated: BuyBuy$0.00
  • Sep 18, 2026
    Stock
    XENE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 4, 2026
    Stock
    NTLA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 2, 2026
    Stock
    QURE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 2, 2026
    Stock
    UTHR
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $675.00
  • Aug 31, 2026
    Stock
    JAZZ
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $300.00
  • Aug 30, 2026
    Stock
    PTCT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $90.00
  • Aug 30, 2026
    Stock
    ARWR
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 26, 2026
    Stock
    JAZZ
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $300.00
  • Aug 25, 2026
    Stock
    ANAB
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 24, 2026
    Stock
    UTHR
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $675.00
  • Aug 18, 2026
    Stock
    AMLX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 16, 2026
    Stock
    DRUG
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00

Joseph’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Joseph Thome’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Joseph Thome ranks #604 of 1,000 with a 4.8★ rating. 58.6% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 63.3% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Joseph Thome’s success rate is 48.5% by the ranking source and 58.6% by Exent’s price-target hit-rate backtest, with a median of 90 days to reach a target.

Joseph Thome (TD Cowen) covers 30 stocks, mostly in healthcare. The most frequently rated are UTHR, ANAB, PTCT, AXSM, VRDN.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.